Logos Bio Rises 5.21% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 14th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 5.71% compared to the previous day, showing strong performance, while Logos Bio, a related stock attracting attention, surged by 5.21% compared to the previous day. Logos Bio is known as a manufacturer of biotechnology equipment and consumables.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to provisional data compiled at 13:36, foreigners are net buying 9,400 shares of Logos Bio.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Logos Bio’s quant financial score is 15.85 points, ranking 13th within the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme, with higher growth and stability scores than the average of other related stocks. This indicates that compared to other stocks in the theme, Logos Bio’s sales and net profit growth rates are relatively fast, and its ability to respond to changes in domestic and international economic environments is also favorable.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of analysis by the Robo Algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.